Intervention

benralizumab

ClinicalTrials.gov intervention label

Clinical trials4

Recruiting3

Common conditions8

Lead sponsors shown2

Clinical trials

4 shown

A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in ItalyNCT07214753 · 2025-12-20

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With BenralizumabNCT06862206 · 2025-07-11

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentNCT06750289 · 2025-03-28

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic SyndromeNCT02130882 · 2014-05-19

Common conditions

Anti-Asthmatic Agents1 Chronic Obstructive Pulmonary Disease1 Eosinophilic Asthma1 Hematologic Diseases1 Hypereosinophilia1 Leukocyte Disorders1 Respiratory System Agents1 Severe Eosinophilic Asthma1

Leading sponsors

AstraZeneca3 National Institute of Allergy and Infectious Diseases (NIAID)1

Trial status mix

RECRUITING3

UNKNOWN1

Phase mix

PHASE32

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.